# Pancreatitis and raised pancreatic enzymes on asciminib, ponatinib, nilotinib and bosutinib: monitoring, hold and stop rules

Source: https://onco.cc/protocols/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs/  
OnCo record `pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Asciminib, ponatinib, nilotinib and bosutinib can raise two pancreas enzymes in the blood, lipase and amylase, and can sometimes inflame the pancreas (pancreatitis). Blood tests look for this: monthly on asciminib and nilotinib, and every 2 weeks for the first 2 months on ponatinib. Tell your team right away about sudden or severe stomach pain, feeling sick or being sick.

## Summary

Scope: adults taking asciminib, ponatinib, nilotinib or bosutinib. The rules are the labels' own; a unit's protocol and the treating haematologist's judgement come first.

Asciminib (US label and EU SmPC agree): assess lipase and amylase monthly, or as clinically indicated, and more often after past pancreatitis. Asymptomatic amylase or lipase above 2 x ULN: withhold until below 1.5 x ULN, then resume at a reduced dose; permanently discontinue if it recurs at the reduced dose; if it does not resolve, permanently discontinue and perform diagnostic tests to exclude pancreatitis. With abdominal symptoms: temporarily withhold and consider tests to exclude pancreatitis. In the US label's 556 patients, enzymes rose in 20% (grade 3 in 7%, grade 4 in 2%) and pancreatitis occurred in 2%.

Ponatinib: lipase every 2 weeks for the first 2 months, then monthly (US) or periodically (EU). The two labels differ. US: lipase above 1 to 1.5 x ULN, consider interrupting; above 1.5 to 2 x ULN, or 2 to 5 x ULN without symptoms, or asymptomatic radiologic pancreatitis, interrupt until below 1.5 x ULN and resume at the next lower dose; lipase 2 to 5 x ULN with symptoms, symptomatic grade 3 pancreatitis, or above 5 x ULN without symptoms, interrupt until symptoms resolve and lipase is grade 0 or 1, then resume at the next lower dose; symptomatic pancreatitis with lipase above 5 x ULN, discontinue. EU: at grade 2, continue at the same dose; for asymptomatic lipase above 5 x ULN or grade 3 pancreatitis, withhold and resume one dose level lower (45 to 30 to 15 mg), and at 15 mg discontinuation should be considered; grade 4, discontinue. The US label's warning says pancreatitis occurred in 26% to 34% of patients across three trials, serious or severe (grade 3 or 4) in 15% to 17%; its adverse reaction tables print the same figures for two of the trials under "Pancreatitis/lipase elevation", a term it does not define, so the count is not clinical pancreatitis alone.

Nilotinib: lipase monthly or as clinically indicated. US: for lipase or amylase of grade 3 or above in adults, withhold and resume at 400 mg once daily when grade 1 or less. EU: for grade 3 to 4 lipase, reduce to 400 mg once daily or interrupt. Bosutinib: the EU SmPC asks for interruption, and tests to be considered, when raised lipase comes with abdominal symptoms; the US label has no pancreatitis warning and no lipase schedule.

The ELN's 2016 consensus (not graded) recommends withholding for asymptomatic grade 3 enzymes, a CT scan where there are symptoms, stopping nilotinib for grade 3 pancreatitis or a positive scan, and stopping any TKI for grade 4. The ELN's 2025 recommendations call nilotinib inadvisable after past pancreatitis; the 2020 edition also preferred TKIs other than bosutinib. CTCAE version 5.0 puts grade 3 lipase at above 2 to 5 x ULN with signs or symptoms, or above 5 x ULN without; version 6.0 moves that lower boundary from 2 to 3 x ULN.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: raised lipase on TKIs; raised amylase on TKIs; lipase monitoring on asciminib; lipase monitoring on ponatinib; pancreatitis on ponatinib; pancreatitis on nilotinib; pancreatic toxicity of BCR::ABL1 inhibitors; pancreatic enzyme elevation on CML treatment

## Connected records

- protocols: [Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant](https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/), [Raised liver enzymes on targeted anticancer drugs: monitoring, hold and stop rules](https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/), [Bosutinib](https://onco.cc/drugs/bosutinib/), [Nilotinib](https://onco.cc/drugs/nilotinib/), [Ponatinib](https://onco.cc/drugs/ponatinib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Dose reduction, interruption and discontinuation](https://onco.cc/terms/dose-modification/)

---
JSON: https://onco.cc/api/v1/entities/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs.json